Siga Technologies (NASDAQ:SIGA – Get Free Report) and Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.
Insider and Institutional Ownership
55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Siga Technologies and Lexaria Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Siga Technologies | -5.19% | -1.55% | -1.32% |
| Lexaria Bioscience | N/A | -174.93% | -143.89% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Siga Technologies | $94.57 million | 2.49 | $23.28 million | ($0.05) | -65.60 |
| Lexaria Bioscience | $710,000.00 | 9.51 | -$11.90 million | ($5.10) | -0.63 |
Siga Technologies has higher revenue and earnings than Lexaria Bioscience. Siga Technologies is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Siga Technologies and Lexaria Bioscience, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Lexaria Bioscience | 1 | 0 | 1 | 0 | 2.00 |
Lexaria Bioscience has a consensus target price of $22.50, indicating a potential upside of 603.12%. Given Lexaria Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Siga Technologies.
Risk and Volatility
Siga Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
